Active substance
Clonidine
- US FDA 73
- Health Canada 14
- US price lines 9
- NHS prices 4
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CATAPRES-TTS-1 | 0.1MG/24HR | system · transdermal | LAVIPHARM | Prescription | 10 Oct 1984 |
| CATAPRES-TTS-2 | 0.2MG/24HR | system · transdermal | LAVIPHARM | Prescription | 10 Oct 1984 |
| CATAPRES-TTS-3 | 0.3MG/24HR | system · transdermal | LAVIPHARM | Prescription | 10 Oct 1984 |
| CLONIDINE HYDROCHLORIDE | 0.1MG | tablet · oral | ACTAVIS ELIZABETH | Prescription | 16 Dec 1986 |
| CLONIDINE HYDROCHLORIDE | 0.2MG | tablet · oral | ACTAVIS ELIZABETH | Prescription | 16 Dec 1986 |
| CLONIDINE HYDROCHLORIDE | 0.3MG | tablet · oral | ACTAVIS ELIZABETH | Prescription | 16 Dec 1986 |
| CLONIDINE HYDROCHLORIDE | 0.3MG; 0.2MG; 0.1MG; 0.05MG | tablet · oral | TP ANDA HOLDINGS | Prescription | 4 Sep 1987 |
| CLONIDINE HYDROCHLORIDE | 0.3MG; 0.1MG; 0.2MG | tablet · oral | CHARTWELL MOLECULES | Prescription | 5 Apr 1988 |
| CLONIDINE HYDROCHLORIDE | 0.2MG; 0.1MG; 0.3MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 31 Aug 1988 |
| DURACLON | 1MG/10ML (0.1MG/ML) | injectable · injection | MYLAN INSTITUTIONAL | Prescription | 2 Oct 1996 |
| CLONIDINE HYDROCHLORIDE | 0.1MG; 0.2MG; 0.3MG | tablet · oral | PRINSTON INC | Prescription | 9 Mar 2007 |
| CLONIDINE HYDROCHLORIDE | 0.1MG; 0.2MG; 0.3MG | tablet · oral | UNICHEM | Prescription | 26 Aug 2009 |
| CLONIDINE HYDROCHLORIDE | 0.1MG; 0.2MG; 0.3MG | tablet · oral | IMPAX LABS | Prescription | 27 Aug 2009 |
| NEXICLON XR | EQ 0.17MG BASE | tablet, extended release · oral | ROSEMONT PHARMACEUTICALS LLC | Prescription | 3 Dec 2009 |
| CLONIDINE | 0.1MG/24HR; 0.2MG/24HR; 0.3MG/24HR | system · transdermal | MYLAN TECHNOLOGIES | Prescription | 16 Jul 2010 |
| CLONIDINE | 0.1MG/24HR; 0.2MG/24HR; 0.3MG/24HR | system · transdermal | DR REDDYS LABS SA | Prescription | 20 Aug 2010 |
| CLONIDINE HYDROCHLORIDE | 1MG/10ML (0.1MG/ML); 5MG/10ML (0.5MG/ML) | injectable · injection | HIKMA FARMACEUTICA | Prescription | 26 Jan 2011 |
| CLONIDINE HYDROCHLORIDE | 1MG/10ML (0.1MG/ML); 5MG/10ML (0.5MG/ML) | injectable · injection | FRESENIUS KABI USA | Prescription | 8 Jul 2011 |
| CLONIDINE HYDROCHLORIDE | 0.1MG; 0.2MG; 0.3MG; 0.05MG | tablet · oral | ALEMBIC PHARMS LTD | Prescription | 6 Dec 2011 |
| CLONIDINE HYDROCHLORIDE | 0.1MG; 0.2MG; 0.3MG | tablet · oral | YUNG SHIN PHARM | Prescription | 13 Jun 2013 |
| CLONIDINE HYDROCHLORIDE | 1MG/10ML (0.1MG/ML); 5MG/10ML (0.5MG/ML) | injectable · injection | XGEN PHARMS | Prescription | 29 Oct 2013 |
| CLONIDINE HYDROCHLORIDE | 1MG/10ML (0.1MG/ML); 5MG/10ML (0.5MG/ML) | injectable · injection | ZYDUS PHARMS | Prescription | 20 Feb 2014 |
| CLONIDINE | 0.1MG/24HR; 0.2MG/24HR; 0.3MG/24HR | system · transdermal | ACTAVIS LABS UT INC | Prescription | 6 May 2014 |
| CLONIDINE HYDROCHLORIDE | 0.1MG | tablet, extended release · oral | ACTAVIS ELIZABETH | Prescription | 15 May 2015 |
| CLONIDINE HYDROCHLORIDE | 0.1MG | tablet, extended release · oral | CHARTWELL RX | Prescription | 23 Oct 2017 |
48 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CLONIDINE | 02538490 | 0.1 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CLONIDINE | 02538504 | 0.2 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CLONIDINE | 02540061 | 0.025 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| JAMP CLONIDINE | 02528207 | 0.025 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MAR-CLONIDINE | 02524198 | 0.025 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MINT-CLONIDINE | 02462192 | 0.1 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-CLONIDINE | 02462206 | 0.2 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-CLONIDINE | 02534738 | 0.025 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| SANDOZ CLONIDINE | 02515784 | 0.1 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ CLONIDINE | 02515792 | 0.2 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ CLONIDINE | 02516217 | 0.025 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-CLONIDINE | 02046121 | 0.1 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-CLONIDINE | 02046148 | 0.2 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-CLONIDINE | 02304163 | 0.025 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CLONIDINE 0.1 MG/DAY PATCH | $6.64381 | per EA | 30 Sep 2026 |
| US NADAC | CLONIDINE 0.2 MG/DAY PATCH | $9.04585 | per EA | 23 Sep 2026 |
| US NADAC | CLONIDINE 0.3 MG/DAY PATCH | $12.29116 | per EA | 30 Sep 2026 |
| US NADAC | CLONIDINE HCL 0.1 MG TABLET | $0.02411 | per EA | 23 Sep 2026 |
| US NADAC | CLONIDINE HCL 0.2 MG TABLET | $0.03299 | per EA | 23 Sep 2026 |
| US NADAC | CLONIDINE HCL 0.3 MG TABLET | $0.04075 | per EA | 23 Sep 2026 |
| US NADAC | CLONIDINE HCL ER 0.1 MG TABLET | $0.21173 | per EA | 23 Sep 2026 |
| US NADAC | CLONIDINE HCL ER 0.17 MG TAB | $15.23568 | per EA | 23 Sep 2026 |
| US NADAC | JAVADIN 0.02 MG/ML SOLUTION | $1.52934 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Clonidine 100microgram tablets | £10.05 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Clonidine 150micrograms/1ml solution for injection ampoules | £4.18 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Clonidine 25microgram tablets | £4.05 | 112 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Clonidine 50micrograms/5ml oral solution sugar free | £197.91 | 100 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 7 May 2025 ONYDA XR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 6 Feb 2020 KAPVAY — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.